- Research Areas
- Clinical Research
We make tomorrow’s treatments available to patients today through innovative clinical trials found only here.
We make tomorrow’s treatments available to patients today through innovative clinical trials found only here.
2024 Clinical Trials Facts
10K
patients in clinical trials
1,556
clinical trials
MD Anderson has the nation's largest cancer clinical trials program, and our Cancer Network® partners across the country allow us to enroll a different and diverse patient population into trials: key to achieving our mission of Making Cancer History®.
Patients and Caregivers:
Discover our clinical trials that offer access to cutting-edge treatments
Office of Clinical Research
Providing high-quality, efficient infrastructure support for all aspects of clinical protocol research

Clinical research helps drive our mission
Featured Clinical Trial Articles
News

ASCO: Novel CAR T therapy and shorter targeted therapy durations...

Pre- and post-surgical immunotherapy improves outcomes for...

AACR: Trio of studies highlights promising early results with...

AACR: Combination treatment is well-tolerated, shows antitumor...

Radiation before mastectomy cuts time delays for reconstructive...

Biomarker-directed combination effective in...

Immunotherapy before surgery leads to promising long-term...

CD19-targeted CAR NK cell therapy achieves promising one-year...
Immunotherapy
Immunotherapy approaches unleash our immune systems against cancer. MD Anderson has more than 160 clinical trials testing drugs and cellular therapies that stimulate and support immune attack against many different types of cancer. The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.


Our human research protection program has rigorous quality standards and has been granted full accreditation by the Association for the Accreditation of Human Research Protection Programs, Inc.